Comprehensive Psychiatry
Volume 45, Issue 1 , Pages 10-15, January 2004

Insight in obsessive compulsive disorder and body dysmorphic disorder

  • Jane L Eisen

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jane L. Eisen, M.D., Butler Hospital, 345 Blackstone Blvd, Providence, RI 02906, USA
    • Brown Medical School, Providence, RI, USA
  • ,
  • Katharine A Phillips

      Affiliations

    • Brown Medical School, Providence, RI, USA
  • ,
  • Meredith E Coles

      Affiliations

    • Department of Psychology, Binghamton University, Binghamton, NY, USA
  • ,
  • Steven A Rasmussen

      Affiliations

    • Brown Medical School, Providence, RI, USA

Abstract 

Similarities between obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) have been described in terms of clinical presentation, comorbidity rates, treatment response profiles, and other features. This is the first study to compare insight in OCD and BDD measuring global insight and numerous components of insight. We compared insight in 64 adult outpatients with DSM-IV OCD and 85 adult outpatients with DSM-IV BDD using a reliable and valid measure (the Brown Assessment of Beliefs Scale [BABS]). BDD patients had significantly poorer global insight than OCD patients. BDD patients also had significantly poorer insight on the following components of insight: conviction that the belief is accurate, perception of other’s views of the belief, explanation for differing views, willingness to consider that the belief is wrong, and recognition that the belief has a psychiatric/psychological cause. Poorer insight was significantly positively correlated with more severe symptoms of the disorder only in the BDD group.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by Pfizer Pharmaceuticals (J.L.E.) and by a National Institute of Mental Health grant (R29-MH54841) and an unrestricted grant from Solvay Pharmaceuticals and Pharmacia and Upjohn to K.A.P.

PII: S0010-440X(03)00172-X

doi:10.1016/j.comppsych.2003.09.010

Comprehensive Psychiatry
Volume 45, Issue 1 , Pages 10-15, January 2004